Details for Patent: 7,820,694
✉ Email this page to a colleague
| Title: | Beta-2-adrenoreceptor agonists |
| Abstract: | Compounds of formula ##STR00001## in free or salt or solvate form, where Ar is a group of formula ##STR00002## Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases. |
| Inventor(s): | Cuenoud; Bernard (Horsham, GB), Bruce; Ian (Horsham, GB), Fairhurst; Robin A (Horsham, GB), Beattie; David (Horsham, GB) |
| Assignee: | Novartis AG (Basel, CH) |
| Filing Date: | Oct 13, 2009 |
| Application Number: | 12/577,855 |
| Claims: | 1. A combination comprising (a) (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one in free or salt or solvate form; and (b) an anticholinergic or antimuscarinic agent. 2. A combination according to claim 1, in which (a) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate. 3. A combination according to claim 1, in which (b) is an anticholinergic or antimuscarinic agent selected from the group consisting of ipratropium bromide, oxitropium bromide and tiotropium bromide. 4. A combination according to claim 3, in which (b) is tiotropium bromide. 5. A pharmaceutical composition comprising a combination according to claim 1 and a pharmaceutically acceptable carrier. 6. A pharmaceutical composition according to claim 5, in which (a) is (R)-5-[2-(5,6-diethyl-indan-2-ylarnino)-1-hydroxy-ethyl]-8-hydroxy-1H-qui- nolin-2-one in free or salt or solvate form and in which (b) is, tiotropium bromide. 7. A method of treating a patient with an obstructive or inflammatory airways disease which comprises administering to the patient in need of such treatment a therapeutically effective amount of a combination according to claim 1. 8. A method of treating a patient according to claim 7, in which the disease is chronic obstructive pulmonary or airways disease. |
